{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neuromyelitis+Optica+Spectrum+Disorder+Relapse",
    "query": {
      "condition": "Neuromyelitis Optica Spectrum Disorder Relapse"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 8,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T03:39:01.105Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05204459",
      "title": "MS-ResearchBiomarkerS",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Multiple Sclerosis",
        "Multiple Sclerosis, Relapsing-Remitting",
        "Multiple Sclerosis, Primary Progressive",
        "Multiple Sclerosis, Secondary Progressive",
        "Clinically Isolated Syndrome",
        "Radiologically Isolated Syndrome",
        "Neuromyelitis Optica Spectrum Disorders",
        "Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease",
        "Neurologic Autoimmune Disease",
        "Neurologic Disorder",
        "Healthy Aging"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Cedars-Sinai Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1000,
      "start_date": "2021-11-11",
      "completion_date": "2041-11-11",
      "has_results": false,
      "last_update_posted_date": "2024-02-06",
      "last_synced_at": "2026-05-22T03:39:01.105Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05204459"
    },
    {
      "nct_id": "NCT02276963",
      "title": "Ublituximab for Acute Neuromyelitis Optica (NMO) Relapses",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neuromyelitis Optica",
        "Neuromyelitis Optica Spectrum Disorder"
      ],
      "interventions": [
        {
          "name": "Ublituximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 6,
      "start_date": "2016-01",
      "completion_date": "2019-02-15",
      "has_results": true,
      "last_update_posted_date": "2019-06-06",
      "last_synced_at": "2026-05-22T03:39:01.105Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02276963"
    },
    {
      "nct_id": "NCT01892345",
      "title": "A Randomized Controlled Trial of Eculizumab in AQP4 Antibody-positive Participants With NMO (PREVENT Study)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Neuromyelitis Optica",
        "Neuromyelitis Optica Spectrum Disorder"
      ],
      "interventions": [
        {
          "name": "Eculizumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alexion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 143,
      "start_date": "2014-04-11",
      "completion_date": "2018-07-17",
      "has_results": true,
      "last_update_posted_date": "2019-06-26",
      "last_synced_at": "2026-05-22T03:39:01.105Z",
      "location_count": 19,
      "location_summary": "Scottsdale, Arizona • Carlsbad, California • Washington D.C., District of Columbia + 15 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Carlsbad",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01892345"
    },
    {
      "nct_id": "NCT04155424",
      "title": "A Study of the Safety and Activity of Eculizumab in Pediatric Participants With Relapsing Neuromyelitis Optica Spectrum Disorder",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Neuromyelitis Optica",
        "Neuromyelitis Optica Spectrum Disorder"
      ],
      "interventions": [
        {
          "name": "Eculizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alexion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 5,
      "start_date": "2020-01-14",
      "completion_date": "2023-07-31",
      "has_results": true,
      "last_update_posted_date": "2024-09-25",
      "last_synced_at": "2026-05-22T03:39:01.105Z",
      "location_count": 15,
      "location_summary": "San Francisco, California • Washington D.C., District of Columbia • Miami, Florida + 11 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04155424"
    },
    {
      "nct_id": "NCT07010302",
      "title": "Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab, and Eculizumab in NMOSD",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "NMOSD"
      ],
      "interventions": [
        {
          "name": "Rituximab (R)",
          "type": "DRUG"
        },
        {
          "name": "Eculizumab (Soliris®)",
          "type": "DRUG"
        },
        {
          "name": "Ravulizumab",
          "type": "DRUG"
        },
        {
          "name": "Satralizumab",
          "type": "DRUG"
        },
        {
          "name": "Inebilizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 540,
      "start_date": "2026-05",
      "completion_date": "2030-05",
      "has_results": false,
      "last_update_posted_date": "2026-03-16",
      "last_synced_at": "2026-05-22T03:39:01.105Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07010302"
    },
    {
      "nct_id": "NCT04131764",
      "title": "Diagnosis of ON With or Without MS or NMOSD",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Multiple Sclerosis",
        "Neuromyelitis Optica Spectrum Disorder Attack",
        "Neuromyelitis Optica Spectrum Disorder Relapse",
        "Neuromyelitis Optica Spectrum Disorder Progression",
        "Optic Neuritis"
      ],
      "interventions": [
        {
          "name": "Reflex (Brightlamp Inc., Purdue University)",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Jagannadha R Avasarala",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 112,
      "start_date": "2019-10-04",
      "completion_date": "2022-09-06",
      "has_results": false,
      "last_update_posted_date": "2022-11-14",
      "last_synced_at": "2026-05-22T03:39:01.105Z",
      "location_count": 1,
      "location_summary": "Lexington, Kentucky",
      "locations": [
        {
          "city": "Lexington",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04131764"
    },
    {
      "nct_id": "NCT02003144",
      "title": "An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Neuromyelitis Optica",
        "Neuromyelitis Optica Spectrum Disorder"
      ],
      "interventions": [
        {
          "name": "eculizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Alexion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 119,
      "start_date": "2015-01-12",
      "completion_date": "2021-07-12",
      "has_results": true,
      "last_update_posted_date": "2022-08-23",
      "last_synced_at": "2026-05-22T03:39:01.105Z",
      "location_count": 19,
      "location_summary": "Scottsdale, Arizona • Oceanside, California • Washington D.C., District of Columbia + 15 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Oceanside",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02003144"
    },
    {
      "nct_id": "NCT04201262",
      "title": "An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Neuromyelitis Optica",
        "Neuromyelitis Optica Spectrum Disorder"
      ],
      "interventions": [
        {
          "name": "Ravulizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Alexion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 58,
      "start_date": "2019-12-09",
      "completion_date": "2024-10-31",
      "has_results": true,
      "last_update_posted_date": "2025-10-14",
      "last_synced_at": "2026-05-22T03:39:01.105Z",
      "location_count": 10,
      "location_summary": "Aurora, Colorado • Fort Collins, Colorado • Washington D.C., District of Columbia + 7 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Fort Collins",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04201262"
    }
  ]
}